Goldfinch Bio Announces Upcoming Presentation of Phase 1 Clinical Data for Lead Precision Kidney Therapeutic Candidate, GFB-887, and Expansion of Scientific Leadership Team
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that it will present clinical data from a Phase 1 study of its lead precision kidney therapeutic candidate, GFB-887, at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting,…